Why this expert has a 'positive long-term view' on the CSL share price

Is there a potential buying opportunity for CSL shares?

| More on:
doctor making thumbs up gesture and holding vial labelled 'covid-19 vaccine' representing covid shares

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • The CSL share price is holding up against the market sell-off this morning as experts recommend investors buy the shares
  • Medallion Financial Group rates CSL a long-term buy due to new technology and demand for flu vaccines
  • Two other brokers have also reiterated their buy recommendations on the shares last week following a favourable court ruling for the blood donation industry

Our market is in for a rough ride but the weakness could present longer-term investors with a buying opportunity for CSL Limited (ASX: CSL) shares.

Shares in the global biotech slipped 0.1% in early trade before bouncing 0.2% higher at $278.72.

That's a good outcome given that the S&P/ASX 200 Index (ASX: XJO) crashed 1.5% on recession fears.

Why the CSL share price is a long-term buy

The volatility is likely to stay for a while, but that won't change the positive view on the shares from Medallion Financial Group's Jean-Claude Perrottet.

New technology and demand for flu vaccinations are some of the reasons for his "buy" recommendation on the CSL share price, according to The Bull. He said:

Full year results for this blood products company were positive in response to strong demand for flu vaccines, in our view.

CSL is rolling out new technology in the US, which reduces plasma donation procedure times by about 30 per cent. These innovations should improve the collection process and, as a result, we retain a positive long-term view on CSL.

Court ruling gives a secondary boost

He isn't the only one that is bullish on the CSL share price either. This is particularly so after a US District Court for the District of Columbia issued a favourable ruling on blood donations.

The preliminary injection prevents US border officials from enforcing a ban on paid plasma donations from Mexicans that enter the US on USB1/B2non-immigrant visas, noted Morgan Stanley.

US border officials had previously said that such donations were a violation of the terms of the visa.

What is the CSL share price worth?

Morgan Stanley commented:

CSL has 304 centers in the US with ~16 near the US/Mexican Border – which we estimate may have accounted for ~10% of plasma collections. If the US border issue is resolved this would be a clear positive for CSL.

Morgan Stanley has an overweight recommendation on the CSL share price with a price target of $323 a share.

This positive view was echoed by Citigroup, although the broker doesn't think this development has a major impact on CSL.

Citi said:

This is a positive for the industry which has just recently seen plasma collections reach pre-pandemic levels. For CSL the impact will positive, but relatively small.

Nonetheless, Citi is recommending investors buy the CSL share price. Its 12-moth price target is $340 a share.

Should you invest $1,000 in Opthea Limited right now?

Before you buy Opthea Limited shares, consider this:

Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and Opthea Limited wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

And right now, Scott thinks there are 5 stocks that may be better buys...

See The 5 Stocks *Returns as of 30 April 2025

Motley Fool contributor Brendon Lau has positions in CSL Ltd. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Broker Notes

Mum playing with her baby boy holding him on her tummy as she lays down while smiling about the Bubs share price going up today
Broker Notes

Macquarie tips 80% upside for this ASX All Ords healthcare stock

This out of favour stock could be primed for a rebound.

Read more »

Man drawing an upward line on a bar graph symbolising a rising share price.
Broker Notes

Macquarie tips 40% upside for this ASX 200 real estate stock

Let's see what the broker is saying about this stock.

Read more »

Woman sits at her desk working at night, while traffic flows on a busy freeway out the window behind her.
Broker Notes

Transurban shares: Buy, hold, sell? Here's Macquarie's recommendation

Macquarie’s analysts just ran their slide rules over Transurban shares. Here’s what they found.

Read more »

A woman sits at her home computer with baby on her lap, and the winning ticket in her hand.
Consumer Staples & Discretionary Shares

Which 'enduring high-quality business' has become a forgotten ASX 200 stock?

Fundie says this ASX 200 consumer discretionary stock has been flying under investors' radar.

Read more »

A woman sits at her computer with her chin resting on her hand as she contemplates her next potential investment.
Financial Shares

Want a financial stock outside the big 4 banks? Macquarie tips 15% upside for this small cap financial

For those searching on the edges, this name could be worth a second look according to Macquarie.

Read more »

Copal miner standing in front of coal.
Resources Shares

How much upside does Macquarie tip for New Hope shares?

A softer-than-expected quarter has impacted the broker's view.

Read more »

Happy man working on his laptop.
Broker Notes

Leading brokers name 3 ASX shares to buy today

Here's why brokers believe that now could be the time to snap up these shares.

Read more »

Two funeral workers with a laptop surrounded by cofins.
Broker Notes

Macquarie just forecast this ASX 300 dividend share could surge 37%. Here's why

Atop its passive income payouts, Macquarie expects this ASX dividend stock could leap 37% in a year.

Read more »